Needham Maintains Buy on ResMed, Raises Price Target to $224
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Mike Matson maintains a Buy rating on ResMed (NYSE:RMD) and raises the price target from $215 to $224, indicating a positive outlook on the company's stock.
April 01, 2024 | 9:22 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Mike Matson maintains a Buy rating on ResMed and raises the price target from $215 to $224, signaling confidence in the company's future performance.
The increase in price target by a reputable analyst suggests a strong belief in ResMed's potential for growth and profitability, likely leading to increased investor confidence and a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100